Atara Biotherapeutics (Atara Biotherapeutics) GF Value Rank : 2 (As of Apr. 24, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Atara Biotherapeutics GF Value Rank?

Atara Biotherapeutics has the GF Value Rank of 2.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Atara Biotherapeutics's GF Value Rank

For the Biotechnology subindustry, Atara Biotherapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atara Biotherapeutics's GF Value Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's GF Value Rank falls into.

Atara Biotherapeutics GF Value Rank Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Atara Biotherapeutics (Atara Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

AT2:Germany AT2:Germany

Address

2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320

Website

https://www.atarabio.com

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Executives

Jill Henrich	officer: EVP, Global Head RA & Quality	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Pascal Touchon	director, officer: President and CEO	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD SUITE 900, SOUTH SAN FRANCISCO CA 94080
Amar Murugan	officer: SVP, GC & Secretary	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD,SUITE 900, SOUTH SAN FRANCISCO CA 94080
Eric J Hyllengren	officer: SVP, CFO	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Anhco Nguyen	officer: EVP, Chief Sci. & Tech Officer	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Manher Joshi	officer: EVP, Chief Medical Officer	2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS CA 91320
Carol Giltner Gallagher	director	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Eric Dobmeier	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
William K Heiden	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Charlene A. Banard	officer: EVP, Chief Technical Officer	C/O APPLIED MOLECULAR TRANSPORT INC., 450 EAST JAMIE COURT, SOUTH SAN FRANCISCO CA 94080
Jakob Dupont	officer: EVP, Head of R&D	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Utpal Koppikar	officer: Chief Financial Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Ameet Mallik	director	C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Kristin Yarema	officer: Chief Commercial Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Joe Newell	officer: Chief Tech. Operations Officer	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO CA 94080